Mark Mendel, PhD
Chief Executive Officer, Founder
Mark Mendel is Managing Director at Mendel Consulting, LLC. Previously he was a Senior Consultant at Broadmark Capital, LLC. Mark also previously served as managing director of RiverVest Venture Partners, which he co-founded. While at RiverVest, he served as founding CEO and later Chairman of the Board of Auxeris Therapeutics. He also led investments in and served as a member of the board of CyDex (acquired by Ligand Pharma) and as a board observer at Conforma Therapeutics (acquired by Biogen-Idec), CGI Pharmaceuticals (acquired by Gilead) and Xcyte Therapeutics (acquired by Cyclacel Pharmaceuticals). Before RiverVest, Mark was a vice president with ARCH Venture Partners. Mark has also worked in medical research at the Scheie Eye Institute and at Massachusetts General Hospital, in product development at ALYX Medical, an in vitro diagnostics start up, and in manufacturing at Polaroid. He has a Ph.D. in bio-engineering from University of Pennsylvania and B.S.M.E from Cornell.
Chief Strategic Officer, COO, Founder
David Therrien’s work as an entrepreneurial technologist leading major art, design and building projects sits at the intersection of biological processes, information systems, and engineering. He brings decades of experience assembling and leading large teams of engineers, scientists, project managers, and technicians to design/build complex multi-million dollar technological installations with difficult, often critical deadlines. He has designed, built, lived and worked in large shipping container studio complexes since 2006. Sponsors/clients of Therrien’s work have included Apple, Warner Bros, Stanford University, the City of Toronto, and the Rockefeller Foundation.